Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: A population-based test-negative case-control study

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Martínez Baz, Iván ^a,b   Martínez Artola, Víctor ^c   Reina, Gabriel ^d   Guevara, Marcela ^a,b   Cenoz, Manuel García ^a,b   Morán, Julio ^e   Irisarri, Fátima ^a,b   Arriazu, Maite ^a,b   Albeniz, Esther ^e   Castilla, Jesús ^a,b  

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Unidad de Patología Crónica Compleja Servicio de Pediatría y Áreas Específicas Hospital Universitario de Navarra Servicio Navarro de Salud Osasunbidea   (Spain)

Author keywords

Case control studies; H1N1 subtype; Influenza A virus; Influenza vaccines; Spain

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MIDDLE AGED; PRESCHOOL CHILD; SENTINEL SURVEILLANCE; SPAIN; STATISTICS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874522717     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-191     Document Type: Article

References (22)

1. Serious morbidity and mortality associated with influenza epidemics. Glezen WP, Epidemiol Rev 1982 4 25 44 6754408 (Pubitemid 13249672)
2. Influenza-associated hospitalizations in the United States. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K, JAMA 2004 292 1333 1340 10.1001/jama.292.11.1333 15367555 (Pubitemid 39223224)
3. Effectiveness of influenza vaccine in the community-dwelling elderly. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E, N Engl J Med 2007 357 1373 1381 10.1056/NEJMoa070844 17914038 (Pubitemid 47535592)
4. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Osterholm MT, Kelley NS, Sommer A, Belongia EA, Lancet Infect Dis 2012 12 36 44 10.1016/S1473-3099(11)70295-X 22032844
5. Assessing vaccine efficacy in the field. Further observations. Orenstein WA, Bernier RH, Hinman AR, Epidemiol Rev 1988 10 212 240 3066628
6. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioners networks. Valenciano M, Kissling E, Ciancio BC, Moren A, Vaccine 2010 28 7381 7388 10.1016/j.vaccine.2010.09.010 20851086
7. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS, Int J Epidemiol 2006 35 337 344 16368725
8. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Jefferson T, Rivetti A, Rudin M, Pietrantonj A, Demicheli V, Lancet 2005 366 1165 1174 10.1016/S0140-6736(05)67339-4 16198765 (Pubitemid 41393594)
9. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA, Int J Epidemiol 2007 36 623 631 10.1093/ije/dym021 17403908 (Pubitemid 47244566)
10. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A, PLoS One 2011 6 11 27622 10.1371/journal.pone.0027622 22110695
11. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C, Thomas D, Sebastianpillai P, Ellis J, Carman W, Wreghitt T, Zambon M, Watson J, Euro Surveill 2011 16 6 ii=19791
12. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Fielding JE, Grant KA, Garcia K, Kelly HA, Emerg Infect Dis 2011 17 1181 1187 10.3201/eid1707.101959 21762570
13. Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón, Spain: Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test negative, hospital-based, case-control study. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez Vilar S, Silvestre-Silvestre E, Calvo-Mas C, Safont-Adsuara L, Ruiz-García M, Vaccine 2010 28 7460 7467 10.1016/j.vaccine.2010.09.042 20875486
14. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Castilla J, Martínez-Artola V, Salcedo E, Martínez-Baz I, Cenoz MG, Guevara M, Alvarez N, Irisarri F, Morán J, Barricarte A, Vaccine 2012 30 195 200 10.1016/j.vaccine.2011.11.024 22100636
15. Recommended virus for influenza vaccines for use in the 2010-2011 northern hemisphere influenza. World Health Organization, Wkly Epidemiol Rec 2010 85 81 92 20210260
16. World Health Organization, Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development Geneva: WHO 2009 http://www.who.int/csr/resources/publications/swineflu/ivr153-20090608-en. pdf
17. Instituto de Salud Pública de Navarra, Protocolo de vacunación antigripal 2010-2011. Boletín Informativo n 59 2010 http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/165169/ BOL59INTCampanaGripe.pdf 23362750
18. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Aguilar I, Reyes M, Martinez-Baz I, Guevara M, Albeniz E, Belza M, Castilla J, Euro Surveill 2012 17 17 ii: 20154
19. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I, N Engl J Med 2009 361 2424 2435 10.1056/NEJMoa0907650 19745215
20. A novel influenza A (H1N1) vaccine in various age groups. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, Liu WD, Li CG, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS, N Engl J Med 2009 361 2414 2423 10.1056/NEJMoa0908535 19846844
21. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Plennevaux E, Sheldon E, Blatter M, Reeves-Haché MK, Denis M, Lancet 2010 375 41 48 10.1016/S0140-6736(09)62026-2 20018365
22. Quantifying the potential role of unmeasured confounders: the example of influenza vaccination. Groenwold RH, Hoes AW, Nichol KL, Hak E, Int J Epidemiol 2008 37 1422 1429 10.1093/ije/dyn173 18725358